Kathy Hancock.

CIGNA will pay the allowed administrative cost, while the authorities shall pay for the vaccine itself. CIGNA will also highly encourage self-insured employers to cover the entire cost to ensure that the greatest number of people are covered. Related StoriesNew vaccine applicant shows great promise at fighting respiratory syncytial virusResearchers reveal why malaria vaccine provides only moderate security among vaccinated childrenNew study may offer approaches for developing toxoplasma-inactivated vaccineCIGNA will communicate important information about H1N1 vaccination through its Internet portal, CIGNA.com. It will educate people through its 24-hour health information line, its case managers and its own Health Advisor nurse teams.Regarding 2387 of the 5599 patients enrolled in the study , the physician had identified that INR measurements could not be obtained or were unlikely to be attained at the requested intervals. Supplement K antagonist therapy was considered to be unsuitable for 1195 sufferers because the threat of stroke was only moderate, as assessed by way of a score of 1 1 on the CHADS2 scale. There were 2092 sufferers who did not want to take supplement K antagonists; regarding 815 patients , this was the only reason that supplement K antagonist therapy was unsuitable. Early Termination of Study The data and safety monitoring committee examined the results of the first planned interim analysis of efficacy on February 19, 2010, of which time 104 events acquired occurred, and observed a treatment benefit in favor of apixaban for the primary outcome that exceeded 4 SD.